Payment overview · 2025
General Payments
$950.86
23 reported records · 10 companies
Healthcare provider profile · identity verified
Richard Slavomir Izewski, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SCHAUMBURG, IL · NPI 1306930177
Verified facts
What the public records show
CMS Open Payments records show Richard Slavomir Izewski, MD received $950.86 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $283.69 | 29.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $148.58 | 15.6% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $118.58 | 12.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $105.03 | 11.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.81 | 10.3% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.38 | 6.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.64 | 5.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.18 | 4.5% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $24.42 | 2.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.55 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $950.86 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $283.69 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $148.58 | 2 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $118.58 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $97.81 | 5 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $61.38 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.46 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.18 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.96 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 142 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 303 | 85 |
| Lisinopril | Lisinopril | 273 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 208 | 59 |
| Metformin Hcl | Metformin Hcl | 201 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 31 |
| Losartan Potassium | Losartan Potassium | 162 | 49 |
| Furosemide | Furosemide | 161 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 45 |
| Omeprazole | Omeprazole | 152 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 41 |
| Gabapentin | Gabapentin | 145 | 34 |
| Eliquis | Apixaban | 142 | 25 |
| Alprazolam | Alprazolam | 134 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 30 |
| Tramadol Hcl | Tramadol Hcl | 105 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 25 |
| Carvedilol | Carvedilol | 98 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 30 |
| Lorazepam | Lorazepam | 87 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 24 |
| Simvastatin | Simvastatin | 77 | 18 |
| Potassium Chloride | Potassium Chloride | 70 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 14 |
| Trazodone Hcl | Trazodone Hcl | 55 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 15 |
| Finasteride | Finasteride | 50 | 11 |
| Azithromycin | Azithromycin | 49 | 26 |
| Spironolactone | Spironolactone | 49 | 12 |
| Jardiance | Empagliflozin | 46 | 14 |
| Amoxicillin | Amoxicillin | 44 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Naproxen | Naproxen | 42 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 11 |
| Glimepiride | Glimepiride | 41 | 12 |
| Meclizine Hcl | Meclizine Hcl | 39 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Allopurinol | Allopurinol | 38 | 14 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 21 |
| Ibuprofen | Ibuprofen | 31 | 12 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Atenolol | Atenolol | 29 | 11 |
| Famotidine | Famotidine | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 23 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 13 |
| Bumetanide | Bumetanide | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Flunisolide | Flunisolide | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $950.86 · 23 records | Novo Nordisk Inc | ABRYSVO, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, GARDASIL 9, JARDIANCE, Livdelzi, Ozempic, PREVNAR 20, PROLIA, Rybelsus, SKYCLARYS, Symbravo, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error